Several GLP‐1 agonists are also being investigated for treating non‐alcoholic steatohepatitis (NASH), a liver disease often associated with obesity and type 2 diabetes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.